Introduction by Croakey: Evidence-based medicine is one of the central tenets of modern healthcare, but when it comes to managing chronic pain, homogenising one-size-fits approaches may be t... Read more
In this second piece for our Monash University Summer Vacation Scholarship series, School of Public Health and Preventative Medicine prize winner Darci Bucheli looks at medical device regula... Read more
The Therapeutic Goods Administration exists to protect the public, but in an age of paleo, Paltrow and celebrity cures, what new challenges does it face? In this Monash University Summer Vac... Read more
In an era of medical apps, remote-controlled biomedical devices and 3D printing, regulatory and quality-control challenges will enter unprecedented territory, the latest Consumers Health For... Read more
Drugs deemed safe and suitable for human use by other jurisdictions could be fast-tracked for approval in Australia under proposed government reforms aimed at reducing red tape and regulatio... Read more
The Pharmaceutical Benefits Advisory Committee and the Therapeutic Goods Administration have been urged to clarify their policies around “biosimilars” – drugs which act in the same way as pa... Read more
Note: A response from the TGA was added on 28 March – see bottom of post. Questions are again being raised about the effectiveness of the Therapeutic Goods Administration as a regulato... Read more
Below is an article that ran earlier this week in the Crikey bulletin raising concerns about the ongoing availability of two pain management medicines, and the processes that have enabled th... Read more
The Therapeutic Goods Administration’s response to concerns about the marketing of a weight-loss pill, which lets you “have the cake without the calories”, suggests that the many revie... Read more